azasetron
≈ 2 min read
Names in other languages
- Englishazasetron
- shAzasetron
- СрпскиAzasetron
- Tiếng ViệtAzasetron
- 日本語アザセトロン
- 中文阿扎司琼
- 简体中文阿扎司琼
- 繁體中文阿扎司瓊
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Azasetron is an antiemetic which acts as a 5-HT 3 receptor antagonist, pK i = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi. Arazasetron besylate (SENS-401) is an investigational drug formulation containing exclusively the R-enantiomer of azasetron. The compound has been studied to prevent hearing loss related to sudden sensorineural hearing loss (SSNHL), acoustic trauma, and cisplatin-induced ototoxicity.
Azasetron is an antiemetic which acts as a 5-HT 3 receptor antagonist, pK i = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi. Arazasetron besylate (SENS-401) is an investigational drug formulation containing exclusively the R-enantiomer of azasetron. The compound has been studied to prevent hearing loss related to sudden sensorineural hearing loss (SSNHL), acoustic trauma, and cisplatin-induced ototoxicity.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1369401441 under CC BY-SA 4.0; modifications have been made.